ArticleArchives of virology2026
Molecular characterization of chikungunya viruses associated with outbreaks in Kenya from 2017 to 2020.
Article in Archives of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging outbreaks of the arbovirus chikungunya virus affect millions of individuals globally, causing debilitating arthralgia and fever. A study on the burden and etiologies of acute febrile illnesses (AFI) in Kenya reported an increase in CHIKV cases in Mombasa between December 2017 and December 2019. In January and February 2020, another outbreak of CHIKV occurred in Dadaab-Hagadera. Using next-generation sequencing on the Illumina MiSeq platform, we established molecular characteristics and phylogenetic differences of the CHIKVs collected from the two epidemiologically distinct settings. Sequenced viruses belonged to the Indian Ocean Lineage and clustered according to geographic region, with E1:K211E and E2:V264A mutations present in both settings. Additional mutations previously reported during Kenyan CHIKV outbreaks and suggested to influence CHIKV adaptation to Aedes albopictus, including E1:T82I and E1:V84D, were also identified. These molecular markers provide useful information on CHIKV spread and can help strengthen outbreak preparedness and response. Clinical features were described only for laboratory-confirmed CHIKV cases from the AFI surveillance cohort and compared with AFI cases testing negative for CHIKV. Sore muscles, headache, and convulsions were more frequently reported among CHIKV-positive participants, whereas diarrhea was less common. No differences were observed in the frequency of cough, skin rash, conjunctivitis, or vomiting. Given the limited number of confirmed CHIKV cases and the predominance of young children in the cohort, the reported clinical symptom associations should only be interpreted as exploratory and warrant confirmation in larger and more representative populations.
Indexed as
Identifiers
42700279What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.